Cite
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
MLA
Hu, Jinsong, et al. “Targeting the Multiple Myeloma Hypoxic Niche with TH-302, a Hypoxia-Activated Prodrug.” Blood, vol. 116, no. 9, Sept. 2010, pp. 1524–27. EBSCOhost, https://doi.org/10.1182/blood-2010-02-269126.
APA
Hu, J., Handisides, D. R., Van Valckenborgh, E., De Raeve, H., Menu, E., Vande Broek, I., Liu, Q., Sun, J. D., Van Camp, B., Hart, C. P., & Vanderkerken, K. (2010). Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood, 116(9), 1524–1527. https://doi.org/10.1182/blood-2010-02-269126
Chicago
Hu, Jinsong, Damian R Handisides, Els Van Valckenborgh, Hendrik De Raeve, Eline Menu, Isabelle Vande Broek, Qian Liu, et al. 2010. “Targeting the Multiple Myeloma Hypoxic Niche with TH-302, a Hypoxia-Activated Prodrug.” Blood 116 (9): 1524–27. doi:10.1182/blood-2010-02-269126.